| Primary | Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48 | T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of body surface area [BSA] estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). | Full Analysis Set: all participants enrolled in the study who applied study cream at least once. Only participants with available data were analyzed. Change from Baseline was calculated as the Week 48 value minus the Baseline value. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline; Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | Participants applied ruxolitinib 1.5% cream BID as monotherapy through Week 12. Participants did not achieve T-VASI25 at Week 12 and added narrow-band ultraviolet B (NB-UVB) phototherapy to their ruxolitinib 1.5% cream BID regimen. NB-UVB phototherapy was given 3 times per week through Week 48 (up to 36 weeks). Participants continued to receive ruxolitinib 1.5% cream BID through Week 48. |
| | | Title | Denominators | Categories |
|---|
| Baseline | - ParticipantsOG00020
- ParticipantsOG00135
| |
| |
| Secondary | Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. | | Posted | | Count of Participants | | Participants | | up to approximately 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | Participants applied ruxolitinib 1.5% cream BID as monotherapy through Week 12. Participants did not achieve T-VASI25 at Week 12 and added narrow-band ultraviolet B (NB-UVB) phototherapy to their ruxolitinib 1.5% cream BID regimen. NB-UVB phototherapy was given 3 times per week through Week 48 (up to 36 weeks). Participants continued to receive ruxolitinib 1.5% cream BID through Week 48. |
| |
| Secondary | Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Each Post-Baseline Visit | An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB |
|
| Secondary | Percentage of Participants Achieving a ≥75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Each Post-Baseline Visit | An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB |
|
| Secondary | Percentage of Participants Achieving a ≥90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Each Post-Baseline Visit | An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB |
|
| Secondary | Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Each Post-Baseline Visit | A T-VASI50 responder achieved ≥50% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 |
|
| Secondary | Percentage of Participants Achieving a ≥75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) Score at Each Post-Baseline Visit | A T-VASI75 responder achieved ≥75% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 |
|
| Secondary | Percentage of Participants Achieving a ≥90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) Score at Each Post-Baseline Visit | A T-VASI90 responder achieved ≥90% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 |
|
| Secondary | Change From Baseline in F-VASI at Each Post-Baseline Visit | F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | |
|
| Secondary | Percentage Change From Baseline in F-VASI at Each Post-Baseline Visit | F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = ([post-Baseline (BL) value minus BL value]/BL value) X 100. | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | |
|
| Secondary | Change From Baseline in T-VASI at Each Post-Baseline Visit | T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value. | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | |
|
| Secondary | Percentage Change From Baseline in T-VASI at Each Post-Baseline Visit | T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = ([post-BL value minus BL value]/BL value) X 100. | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | |
|
| Secondary | Change From Baseline in Facial Body Surface Area (F-BSA) at Each Post-Baseline Visit | F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | percentage of facial surface area | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | Participants applied ruxolitinib 1.5% cream BID as monotherapy through Week 12. Participants did not achieve T-VASI25 at Week 12 and added narrow-band ultraviolet B (NB-UVB) phototherapy to their ruxolitinib 1.5% cream BID regimen. NB-UVB phototherapy was given 3 times per week through Week 48 (up to 36 weeks). Participants continued to receive ruxolitinib 1.5% cream BID through Week 48. |
|
| Secondary | Percentage Change From Baseline in F-BSA at Each Post-Baseline Visit | F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = ([post-Baseline (BL) value minus BL value]/BL value) X 100. | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | Participants applied ruxolitinib 1.5% cream BID as monotherapy through Week 12. Participants did not achieve T-VASI25 at Week 12 and added narrow-band ultraviolet B (NB-UVB) phototherapy to their ruxolitinib 1.5% cream BID regimen. NB-UVB phototherapy was given 3 times per week through Week 48 (up to 36 weeks). Participants continued to receive ruxolitinib 1.5% cream BID through Week 48. |
|
| Secondary | Change From Baseline in Total Body Surface Area (T-BSA) at Each Post-Baseline Visit | T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | percentage of total body surface area | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | Participants applied ruxolitinib 1.5% cream BID as monotherapy through Week 12. Participants did not achieve T-VASI25 at Week 12 and added narrow-band ultraviolet B (NB-UVB) phototherapy to their ruxolitinib 1.5% cream BID regimen. NB-UVB phototherapy was given 3 times per week through Week 48 (up to 36 weeks). Participants continued to receive ruxolitinib 1.5% cream BID through Week 48. |
|
| Secondary | Percentage Change From Baseline in T-BSA at Each Post-Baseline Visit | T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = ([post-BL value minus BL value]/BL value) X 100. | Full Analysis Set. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline; up to Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | Participants applied ruxolitinib 1.5% cream BID as monotherapy through Week 12. Participants did not achieve T-VASI25 at Week 12 and added narrow-band ultraviolet B (NB-UVB) phototherapy to their ruxolitinib 1.5% cream BID regimen. NB-UVB phototherapy was given 3 times per week through Week 48 (up to 36 weeks). Participants continued to receive ruxolitinib 1.5% cream BID through Week 48. |
| |
| Secondary | Plasma Concentration of Ruxolitinib at Weeks 4, 12, and 16 | The concentration of ruxolitinib in the plasma was assessed. | Pharmacokinetic (PK)-Evaluable Population: all participants who applied ruxolitinib 1.5% cream at least once and provided at least 1 post-dose blood sample. Only participants with available data were analyzed. | Posted | | Mean | Standard Deviation | nanomolar | | pre-application at Weeks 4, 12, and 16 | | | | ID | Title | Description |
|---|
| OG000 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | | OG001 | Ruxolitinib 1.5% Cream BID + NB-UVB | Participants applied ruxolitinib 1.5% cream BID as monotherapy through Week 12. Participants did not achieve T-VASI25 at Week 12 and added narrow-band ultraviolet B (NB-UVB) phototherapy to their ruxolitinib 1.5% cream BID regimen. NB-UVB phototherapy was given 3 times per week through Week 48 (up to 36 weeks). Participants continued to receive ruxolitinib 1.5% cream BID through Week 48. |
| |